诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

休市中 06-12 16:00:00 EDT

43.88

-0.08

-0.18%

盘后44.01

+0.13+0.30%

19:58 EDT

最高44.60	最低43.72	成交量1,480万
今开43.94	昨收43.96	日振幅1.99%
总市值1,948亿	流通市值1,399亿	总股本44.39亿
成交额6.53亿	换手率0.46%	流通股本31.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":43.88,"timestamp":1781294400000,"preClose":43.96,"halted":0,"volume":14799174,"hourTrading":{"tag":"盘后","latestPrice":44.0112,"preClose":43.88,"latestTime":"19:58 EDT","volume":169438,"amount":7438333.197,"timestamp":1781308737019,"change":0.1312,"changeRate":0.00299,"amplitude":0.007521},"delay":0,"changeRate":-0.0018198362147406346,"floatShares":3187922885,"shares":4439052849,"eps":4.228648,"marketStatus":"休市中","change":-0.08,"latestTime":"06-12 16:00:00 EDT","open":43.94,"high":44.595,"low":43.72,"amount":653476811.293722,"amplitude":0.019904,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.228648,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":43.96,"dividendRate":0.039242,"preHourTrading":{"tag":"盘前","latestPrice":43.89,"preClose":43.97,"latestTime":"09:29 EDT","volume":388642,"amount":16994521.83032,"timestamp":1781270999827,"change":-0.08,"changeRate":-0.001819,"amplitude":0.018417},"postHourTrading":{"tag":"盘后","latestPrice":44.0112,"preClose":43.88,"latestTime":"19:58 EDT","volume":169438,"amount":7438333.197,"timestamp":1781308737019,"change":0.1312,"changeRate":0.00299,"amplitude":0.007521},"volumeRatio":0.9794337090639029,"optionData":{"bulkOrders":[{"symbol":"NVO","call":false,"expireDate":1792123200000,"strike":"45.0","timestamp":1781292189304,"price":4.59,"volume":2500,"amount":1147500,"type":"-"},{"symbol":"NVO","call":true,"expireDate":1792123200000,"strike":"45.0","timestamp":1781292189304,"price":4.03,"volume":2500,"amount":1007500,"type":"-"}]},"impliedVol":0.4313,"impliedVolPercentile":0.1315},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2643321101","title":"诺和诺德长效生长激素诺泽优将于今年暑期在国内全面上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2643321101","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643321101?lang=zh_cn&edition=full","pubTime":"2026-06-13 17:23","pubTimestamp":1781342580,"startTime":"0","endTime":"0","summary":"南方财经6月13日电，诺和诺德今日宣布，其长效生长激素注射液诺泽优?（帕西生长激素）将于今年暑期在中国全面上市，为因内源性生长激素分泌不足所致生长迟缓的2.5岁及以上的中国儿童患者带来每周一次的治疗新选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606133770590837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVO","NVOX","BK4532","BK4599","BK4585","BK4007","BK4588","LU0154236417.USD","LU1093756325.SGD","NVOH","IE00BZ1G4Q59.USD","LU1093756168.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182087964","title":"英国卫生监管机构批准诺和诺德减肥药Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=1182087964","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182087964?lang=zh_cn&edition=full","pubTime":"2026-06-11 23:19","pubTimestamp":1781191158,"startTime":"0","endTime":"0","summary":"英国药品监管机构周四批准了诺和诺德的减肥药片，为患者提供了一种无需注射的肥胖治疗新选择，同时也巩固了这家丹麦药企相对于美国竞争对手礼来的先发优势。诺和诺德预计，该药将在数周内通过私立处方上市。根据英国国家医疗服务体系的最新估算，英格兰约有30%的成年人受肥胖影响，相当于约1300万至1400万人。诺和诺德这款药片含有司美格鲁肽，与其旗下用于减肥的注射型重磅药物Wegovy及用于糖尿病的Ozempic具有相同的活性成分。","market":"us","thumbnail":"https://community-static.tradeup.com/news/4812f8e146094a91d24ad513651fcb26","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/4812f8e146094a91d24ad513651fcb26"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a4d9db3d57fa8633379c890f70b5f1d9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOX","NVO","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642424467","title":"减肥药概念股普涨 诺和诺德(NVO)涨3.14% 高盛料2030年全球减肥药市场规模将达1140亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642424467","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642424467?lang=zh_cn&edition=full","pubTime":"2026-06-10 22:17","pubTimestamp":1781101035,"startTime":"0","endTime":"0","summary":"高盛新近研究指，预计到2030年，全球减肥药市场规模将达到1140亿美元，较去年12月作出的1010亿美元预测进一步上调约13%，因一系列利好因素正在推动这一赛道从“小众高价市场”向“大众消费级市场”转变。基于这一趋势，高盛预计，到2030年口服减肥药将贡献约460亿美元收入，占全球肥胖症药物市场规模的40%，高于此前预计的350亿美元和35%的市场占比。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/ZjY1NDI1NzQxNDM1Mw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZjY1NDI1NzQxNDM1Mw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301402","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","BK4599","BK4532","BK4007","IE00BZ1G4Q59.USD","LU1093756325.SGD","IE00BKVL7J92.USD","NVOH","BK4585","NVOX","NVO","BK4588","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106268693","title":"异动解读｜诺和诺德盘中上涨3.15%，ADA年会临床数据利好叠加口服Wegovy处方量突破300万份","url":"https://stock-news.laohu8.com/highlight/detail?id=1106268693","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106268693?lang=zh_cn&edition=full","pubTime":"2026-06-10 22:14","pubTimestamp":1781100888,"startTime":"0","endTime":"0","summary":"6月10日，诺和诺德盘中上涨3.15%，报43.52美元/股，成交额1.57亿美元。美国糖尿病协会科学年会期间多项临床数据发布提振市场情绪；同时诺和诺德披露口服版Wegovy（维秀美）自1月上市以来处方量已突破300万份，商业化放量超预期。竞争层面，辉瑞公布埃诺格鲁肽与司美格鲁肽的头对头20周中期数据，诺和诺德随即发布声明回应，称需在更完整数据下综合评估，市场对其积极应对态度反应正面。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642419178","title":"GLP-1赛道竞争加剧  辉瑞“头对头”挑战诺和诺德","url":"https://stock-news.laohu8.com/highlight/detail?id=2642419178","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642419178?lang=zh_cn&edition=full","pubTime":"2026-06-10 09:35","pubTimestamp":1781055326,"startTime":"0","endTime":"0","summary":"新华财经北京6月10日电近日，辉瑞公布其GLP-1受体激动剂埃诺格鲁肽（先维盈?）与诺和诺德司美格鲁肽（诺和盈?）的头对头研究——SLIMMER-UP-SWITCH的20周中期分析结果，显示埃诺格鲁肽在减重数值上略优于司美格鲁肽。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606103766030185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0225284248.USD","LU0985481810.HKD","SG9999002232.USD","LU0456855351.SGD","LU1066051498.USD","NVO","LU0306806265.USD","NVOX","IE00BKVL7J92.USD","LU0868494617.USD","LU1894683264.USD","SGXZ57979304.SGD","LU0306807586.USD","BK4532","BK4534","BK4599","IE00B19Z3B42.SGD","LU0170899867.USD","BK4585","LU0289739699.SGD","SG9999001176.USD","BK4568","BK4550","LU0122379950.USD","IE00BLSP4452.SGD","BK4581","LU1093756325.SGD","LU0234572021.USD","LU1894683348.USD","BK4533","BK4592","LU1883839398.USD","LU0321505439.SGD","LU1093756168.USD","NVOH","LU0058720904.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","LU0225771236.USD","LU2596442595.SGD","LU0154236417.USD","LU1023059063.AUD","IE00BBT3K403.USD","IE00BLSP4239.USD","SG9999011175.SGD","LU0321505868.SGD","PFE","IE00B19Z3581.USD","IE00B3T34201.USD","SG9999001176.SGD","IE000M9KFDE8.USD","SG9999003800.SGD","BK4588","BK4007","SG9999013999.USD","LU1057294990.SGD","IE0002270589.USD","SG9999002224.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131882543","title":"异动解读｜诺和诺德盘中上涨3.13%，ADA年会多项临床数据利好叠加口服减肥药处方量突破300万份","url":"https://stock-news.laohu8.com/highlight/detail?id=1131882543","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131882543?lang=zh_cn&edition=full","pubTime":"2026-06-10 03:07","pubTimestamp":1781032037,"startTime":"0","endTime":"0","summary":"6月10日，诺和诺德盘中上涨3.13%，报42.31美元/股，成交额4.6亿美元。消息面上，多重利好共振推动股价走强。此外，诺和诺德披露口服版Wegovy（维秀美）自1月上市以来处方量已突破300万份，商业化放量超预期，且该药已在阿联酋正式上市，成为美国以外首个落地市场，海外拓展持续推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642137467","title":"多家药企公布“头对头”司美研究数据，诺和诺德坐不住了","url":"https://stock-news.laohu8.com/highlight/detail?id=2642137467","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642137467?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:44","pubTimestamp":1781005440,"startTime":"0","endTime":"0","summary":"减肥药赛道再起波澜！因为一项减肥药的头对头研究数据，诺和诺德向辉瑞“开怼”。6月9日，减肥药巨头诺和诺德中国针对近期在2026年美国糖尿病协会（ADA）科学年会上公布的SLIMMER-UP-SWITCH研究的20周中期分析数据发布了一份说明称：“对于任何单一研究，均需在更完整的数据披露和多维度证据支持下进行综合、科学评估，避免片面解读带来的潜在误导。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606093765289066.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765289066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0170899867.USD","LU1066053197.SGD","SG9999002224.SGD","BK4592","NVO","SG9999002232.USD","BK4599","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0868494617.USD","LU1066051498.USD","BK4007","LU1093756325.SGD","LU1894683264.USD","IE00B3T34201.USD","LU0058720904.USD","LU0321505439.SGD","LU1057294990.SGD","SG9999001176.USD","BK4550","LU1093756168.USD","SG9999011175.SGD","BK4534","IE00B19Z3581.USD","LU0225284248.USD","SG9999001176.SGD","LU1894683348.USD","LU0225771236.USD","IE00BLSP4452.SGD","SG9999003800.SGD","SG9999013999.USD","BK4532","BK4581","LU0289739699.SGD","NVOH","LU2596442595.SGD","LU0306806265.USD","LU1883839398.USD","BK4533","LU0306807586.USD","LU0234572021.USD","LU1023059063.AUD","BK4585","IE00BLSP4239.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","NVOX","BK4568","LU0456855351.SGD","IE00B19Z3B42.SGD","LU0122379950.USD","IE000M9KFDE8.USD","BK4588","LU0154236417.USD","LU0321505868.SGD","IE0002270589.USD","PFE","LU0985481810.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641100049","title":"比司美格鲁肽多减35%体重！辉瑞减肥药能否突破GLP-1药物疗效瓶颈","url":"https://stock-news.laohu8.com/highlight/detail?id=2641100049","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641100049?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:17","pubTimestamp":1780910222,"startTime":"0","endTime":"0","summary":"国内GLP-1减肥药市场的竞争，已从“有无”之争进入到拼疗效阶段。6月8日，辉瑞宣布其GLP-1受体激动剂埃诺格鲁肽与司美格鲁肽的头对头研究（SLIMMER-UP-SWITCH）关键数据，在2026年美国糖尿病协会（ADA）科学年会上作为“最新突破（LateBreaking）”正式公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606083763671017.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606083763671017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999001176.SGD","LU1057294990.SGD","BK4007","IE000M9KFDE8.USD","IE00BBT3K403.USD","LU0122379950.USD","LU0289739699.SGD","LU0234572021.USD","NVOX","SGXZ57979304.SGD","LU0306807586.USD","IE00B19Z3581.USD","BK4588","SG9999013999.USD","IE00B19Z3B42.SGD","BK4599","IE00BZ1G4Q59.USD","BK4550","LU0058720904.USD","LU0985481810.HKD","SG9999003800.SGD","LU1066051498.USD","LU1894683348.USD","LU1093756325.SGD","SG9999002232.USD","IE00BKVL7J92.USD","BK4533","BK4568","IE00BLSP4452.SGD","NVO","LU0321505868.SGD","SG9999001176.USD","BK4592","SG9999002224.SGD","LU0225284248.USD","LU0154236417.USD","BK4532","IE0002270589.USD","LU0456855351.SGD","LU2596442595.SGD","PFE","BK4585","IE00B3T34201.USD","BK4581","LU1894683264.USD","LU0170899867.USD","LU1023059063.AUD","IE00BLSP4239.USD","LU0321505439.SGD","LU0868494617.USD","LU0225771236.USD","LU1066053197.SGD","SG9999011175.SGD","NVOH","LU0306806265.USD","LU1883839398.USD","LU1093756168.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641100657","title":"诺和诺德减肥口服药上市以来处方量已达300万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2641100657","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641100657?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:07","pubTimestamp":1780909620,"startTime":"0","endTime":"0","summary":"诺和诺德表示，其减肥口服药维秀美自1月初上市以来，处方量已超过300万份。　　这家丹麦制药商周日晚间表示，该口服药在美国药店和在线供应商上架12周后，处方量达到100万份，并在随后的10周内又开出了200万份处方。　　维秀美口服药超过80%的新处方是开给首次使用GLP-1类药物的患者。　　在最初于美国推出维秀美口服药后，诺和诺德上周宣布该药物在阿联酋上市，并表示正准备在今年下半年进行更多地区的上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-08/doc-iniaswmn5428087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1093756325.SGD","BK4532","NVOH","NVOX","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4588","BK4007","BK4585","NVO","BK4599","LU0154236417.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641110756","title":"诺和诺德、联合健康盘前跌超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2641110756","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641110756?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:25","pubTimestamp":1780907108,"startTime":"0","endTime":"0","summary":"诺和诺德、联合健康盘前跌超1%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606083763608225.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606083763608225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1037948541.HKD","LU1629891620.HKD","LU2264538146.SGD","LU1267930573.SGD","LU2237443382.USD","LU0528227936.USD","LU2602419157.SGD","IE00BSNM7G36.USD","LU1854103824.USD","LU2237443622.USD","LU0096364046.USD","IE0001KFT4U8.USD","LU1035775433.USD","NVOH","IE00B19Z3B42.SGD","LU0122379950.USD","LU1732799900.SGD","LU0456855351.SGD","BK4533","LU0708994859.HKD","LU1057294990.SGD","LU0912757837.SGD","LU0672654240.SGD","LU0203202063.USD","IE00BKVL7J92.USD","LU0079474960.USD","LU0048584097.USD","LU2271345857.HKD","IE00BJT1NW94.SGD","LU2491050071.SGD","IE00BFTCPJ56.SGD","LU1145028129.USD","BK4585","IE00B7SZLL34.SGD","LU0323591593.USD","LU1066051225.USD","LU2360106947.USD","LU1127390331.HKD","LU1084165304.USD","LU0795875169.SGD","LU0432979614.USD","LU2279689827.SGD","LU1506573853.SGD","SG9999014906.USD","LU2461242641.AUD","LU0006306889.USD","LU2168564065.EUR","LU0203347892.USD","LU0708995401.HKD","LU2417539215.USD","SG9999001176.SGD","LU0061475181.USD","LU2242649171.HKD","LU1267930730.SGD","LU0310800379.SGD","LU2471134796.USD","LU2361044865.SGD","LU0965509283.SGD","LU0787776722.HKD","LU1674673428.USD","LU2237443465.HKD","LU1623119135.USD","IE0005OL40V9.USD","LU0011850046.USD","LU1066051811.HKD","IE00B894F039.SGD","LU2361044949.HKD","IE00BKPKM429.USD","LU2213496289.HKD","LU0496365809.HKD","LU1732800096.USD","IE00BFXG1179.USD","LU1069347547.HKD","SG9999015978.USD","SG9999014880.SGD","LU0353189763.USD","LU2106854487.HKD","UNHG","LU0052756011.USD","LU1003077747.HKD","LU0077335932.USD","LU2237443549.SGD","SG9999018865.SGD","LU1551013425.SGD","SGXZ99366536.SGD","LU0203201768.USD","LU2111349929.HKD","IE00BFSS8Q28.SGD","LU1066051498.USD","LU1778281490.HKD","IE00B19Z8W00.USD","LU0149725797.USD","LU1854104046.USD","LU0882574139.USD","BK4007","LU0820562030.AUD","LU1551013342.USD","ELIS","SG9999015945.SGD","LU2028103732.USD","LU1023059063.AUD","LU2347655156.SGD","LU0471298777.SGD","LU2552382058.USD","IE00BJJMRZ35.SGD","LU0158827948.USD","IE0009355771.USD","IE00B19Z3581.USD","LU1868836591.USD","IE00BZ1G4Q59.USD","LU0203345920.USD","LU2089284900.SGD","LU2362540622.SGD","IE0002270589.USD","IE00BK4W5L77.USD","LU0943347566.SGD","LU0345770308.USD","SG9999014898.SGD","SGXZ51526630.SGD","LU0949170772.SGD","SGXZ81514606.USD","LU2168564222.USD","LU1720051108.HKD","LU2471134952.CNY","LU1496350502.SGD","LU2471134523.USD","LU0029864427.USD","LU0053666078.USD","BK4532","LU0107464264.USD","LU2491050154.USD","LU2468319806.SGD","IE0004445239.USD","LU0256863902.USD","LU0689472784.USD","LU0466842654.USD","LU0417517546.SGD","LU0471298694.HKD","LU0964807845.USD","LU0097036916.USD","LU0211326839.USD","LU0310799852.SGD","LU1868837136.USD","LU2168564149.EUR","LU1267930490.SGD","LU1868837300.USD","LU0683600562.USD","LU0187121727.USD","LU0320765059.SGD","LU0109394709.USD","LU2746668974.SGD","LU0256863811.USD","IE00BKDWB100.SGD","LU1093756168.USD","IE00B4JS1V06.HKD","LU1037948897.HKD","LU1119994496.HKD","LU0345770993.USD","LU0225283273.USD","LU1674673691.USD","IE00B3T34201.USD","LU0889565916.HKD","SGXZ57979304.SGD","LU1267930227.SGD","LU2168563687.JPY","LU1934455863.HKD","LLYZ","LU0289739699.SGD","LU0342679015.USD","LU2756315318.SGD","LU1069344957.HKD","LU0661504455.SGD","IE00BZ9MQY76.HKD","LU2023251221.USD","LU0211328371.USD","LU0128525689.USD","LU0823416689.USD","LU0861579265.USD","LU2896262040.SGD","IE00B19Z9P08.USD","LU2168564495.EUR","LU1983299246.USD","IE00B1BXHZ80.USD","LU0109391861.USD","ELIL","LU2471134879.HKD","LU0058720904.USD","BK4516","LU0823434740.USD","LU1280957306.USD","LU2362541273.HKD","LU2112291526.USD","LU2211815571.USD","LU2237438978.USD","LU1074936037.SGD","LU1712237335.SGD","LU0114720955.EUR","LU2265009873.SGD","LU1670627923.USD","LU0210536198.USD","LU1791710400.SGD","LU0211327993.USD","LU0820561909.HKD","LU1868836757.USD","IE00B2B36J28.USD","LU0198837287.USD","IE00B19Z8X17.USD","LU2244417387.USD","UNH","LU0266013472.USD","IE0004445015.USD","UNHW","IE00B19Z9Z06.USD","LU0133085943.USD","LU1323610961.USD","LU1035773651.USD","LU1804176565.USD","LU1670628061.USD","BK4534","IE00B1XK9C88.USD","LU1291159041.SGD","LU2462157665.USD","IE00BWXC8680.SGD","LU0251132253.USD","LU1720051017.SGD","SG9999018857.SGD","LU2491049909.HKD","LU0786609619.USD","LU2089984988.USD","LLY","BK4588","BK4566","IE00BN29S564.USD","SG9999002224.SGD","NVOX","SG9999013999.USD","IE00BFSS7M15.SGD","SG9999014914.USD","LU2324357040.USD","SG9999017495.SGD","LU1066053197.SGD","LU2063271972.USD","LU0820561818.USD","LU1974910355.USD","LLYX","LU1153585028.USD","LU0354030511.USD","LU0557290698.USD","LU1868836914.USD","IE00BJJMRY28.SGD","LU1917777945.USD","LU0310800965.SGD","LU2456880835.USD","LU1366192091.USD","LU1934455277.USD","LU0738911758.USD","LU2108987350.USD","LU0965508806.USD","LU1934455194.USD","LU2357305700.SGD","LU2750360997.AUD","LU0965509010.AUD","IE00B775H168.HKD","LU0353189680.USD","LU2746668461.USD","LU0094547139.USD","NVO","LU0553294199.USD","LU2362541513.USD","LU1061106388.HKD","LU2087625088.SGD","LU1261432733.SGD","LU0106261372.USD","IE000M9KFDE8.USD","LU1814569148.SGD","SG9999001176.USD","LU2552382132.HKD","LU2756315664.SGD","LU2125154935.USD","SG9999015952.SGD","LU0211326755.USD","LU0795875086.SGD","SG9999002232.USD","LU0158827781.USD","LU2237443978.SGD","LU1232071149.USD","LU0316494557.USD","LU0354030438.USD","LU0154236417.USD","SGXZ31699556.SGD","LU0882574055.USD","BK4581","LU2023250504.SGD","LU1548497426.USD","GB00BDT5M118.USD","LU2750360641.GBP","LU2236285917.USD","LU2133065610.SGD","LU2237443895.HKD","LU2552382215.SGD","LU2023250330.USD","SG9999015986.USD","BK4599","LU2361045086.USD","LU2360032135.SGD","LU1064131342.USD","LU0385154629.USD","LU0976567544.SGD","IE00BJLML261.HKD","LU0234572021.USD","LU0545039389.USD","LU2089283258.USD","IE00B4R5TH58.HKD","IE0002141913.USD","IE00B7KXQ091.USD","IE00BK4W5M84.HKD","LU0320765992.SGD","IE00B19Z9505.USD","LU1914381329.SGD","BK4154","LLII","LU0965509101.SGD","LU1989771016.USD","LU0823434583.USD","LU1093756325.SGD","LU1988902786.USD","LU2125154778.USD","LU0640476718.USD","LU0128525929.USD","LU1791710582.SGD","LU0238689110.USD","IE00BJJMRX11.SGD","LU1718418525.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180373682","title":"诺和诺德：司美格鲁肽2毫克在一年期试验中，糖化血红蛋白达标率与替尔泊肽相当，减重达标率更优","url":"https://stock-news.laohu8.com/highlight/detail?id=1180373682","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180373682?lang=zh_cn&edition=full","pubTime":"2026-06-06 21:04","pubTimestamp":1780751047,"startTime":"0","endTime":"0","summary":"诺和诺德公司研发的司美格鲁肽2毫克剂量，在一项为期一年的临床试验数据中，展现出与礼来公司替尔泊肽在关键血糖控制指标上的同等效力，并在减重效果上实现了超越。\n具体数据显示，接受司美格鲁肽2毫克治疗的患者，其糖化血红蛋白水平成功降至7%以下的比例，与使用替尔泊肽的患者群体相当。然而，在衡量减重效果的另一个关键终点上，司美格鲁肽表现更为突出：治疗一年后，实现体重减轻至少5%的患者比例显著高于替尔泊肽组。\n这一对比结果，为评估这两款在糖尿病与肥胖症治疗领域占据重要地位的药物提供了新的临床依据，凸显了司美格鲁肽在促进显著减重方面的潜在优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0354030438.USD","LU1551013425.SGD","GB00BDT5M118.USD","LU2324357040.USD","LU2361044949.HKD","LU0198837287.USD","SG9999015952.SGD","LU2237443549.SGD","LU0820561909.HKD","LU0708995401.HKD","IE00BFSS8Q28.SGD","LU2602419157.SGD","BK4534","LU1145028129.USD","LU2264538146.SGD","LU2491050071.SGD","LU1093756325.SGD","IE00B4R5TH58.HKD","BK4581","LU1323610961.USD","NVOH","LU0210536198.USD","LU2896262040.SGD","LU0320765992.SGD","LU1093756168.USD","LU2237443622.USD","LLYX","IE00BZ1G4Q59.USD","LU2360106947.USD","SG9999015945.SGD","LU1623119135.USD","IE0001KFT4U8.USD","LU1814569148.SGD","IE0005OL40V9.USD","IE00BJJMRZ35.SGD","LU0106261372.USD","LU1291159041.SGD","LU2089284900.SGD","LU2746668974.SGD","SG9999014906.USD","LU2108987350.USD","IE0004445015.USD","LU1035775433.USD","LU2471134523.USD","IE0002141913.USD","LU1280957306.USD","LU2023251221.USD","LU0109391861.USD","LU0820562030.AUD","SGXZ99366536.SGD","LU1127390331.HKD","IE0009355771.USD","LU1551013342.USD","SG9999015986.USD","SG9999015978.USD","LU2168564222.USD","LU0432979614.USD","LU1720051017.SGD","LU0079474960.USD","SG9999001176.SGD","BK4588","LU2168564149.EUR","LU0683600562.USD","LU0097036916.USD","LU2750360641.GBP","SG9999018865.SGD","IE00BWXC8680.SGD","LU0456855351.SGD","LU2106854487.HKD","LU0109394709.USD","LU1868836591.USD","LU0689472784.USD","LU1868836914.USD","LU2746668461.USD","LU0061475181.USD","LU2471134879.HKD","BK4585","IE00BJJMRY28.SGD","LU0122379950.USD","LU2112291526.USD","LU2213496289.HKD","LU2361045086.USD","IE00BK4W5M84.HKD","LU0158827781.USD","LU0234572021.USD","LU2456880835.USD","LU0266013472.USD","LU0094547139.USD","SGXZ31699556.SGD","LU0158827948.USD","LU0256863811.USD","LU1989771016.USD","LU0823416689.USD","IE00BJJMRX11.SGD","LU0786609619.USD","LU2237443895.HKD","LU2028103732.USD","LU2168564495.EUR","ELIS","LU1983299246.USD","LU2237443382.USD","LU0353189680.USD","LLY","LU1061106388.HKD","LU0006306889.USD","SGXZ51526630.SGD","LU0114720955.EUR","LU2756315664.SGD","BK4007","IE00B775H168.HKD","LU0203201768.USD","IE00BFTCPJ56.SGD","LU0385154629.USD","LU1057294990.SGD","IE00B4JS1V06.HKD","SGXZ81514606.USD","LU0320765059.SGD","LU0238689110.USD","LU2211815571.USD","LU0823434740.USD","LU0820561818.USD","LU0882574055.USD","NVO","IE00B1XK9C88.USD","IE00BKVL7J92.USD","LU0672654240.SGD","LU0203202063.USD","LU1712237335.SGD","SG9999014880.SGD","SGXZ57979304.SGD","SG9999014914.USD","LU2491049909.HKD","LU2237443465.HKD","BK4532","SG9999001176.USD","LU0943347566.SGD","LU0289739699.SGD","LU1868836757.USD","LU0225283273.USD","LU0640476718.USD","LU0882574139.USD","LU0823434583.USD","BK4533","LU0964807845.USD","IE00BKDWB100.SGD","LU1366192091.USD","LU2089984988.USD","LU2271345857.HKD","LU2471134796.USD","LU1232071149.USD","LU2087625088.SGD","LU2461242641.AUD","ELIL","IE00BK4W5L77.USD","LU1720051108.HKD","LU0154236417.USD","LU0471298777.SGD","IE00BJLML261.HKD","LU1974910355.USD","LU2089283258.USD","LU2237443978.SGD","LU2168564065.EUR","LU0096364046.USD","SG9999018857.SGD","LU2023250504.SGD","LU0354030511.USD","LU2471134952.CNY","IE00BKPKM429.USD","LLYZ","LU2357305700.SGD","LU2552382058.USD","LLII","LU0471298694.HKD","IE00B1BXHZ80.USD","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00BN29S564.USD","BK4516","SG9999014898.SGD","LU2265009873.SGD","LU1069344957.HKD","LU2750360997.AUD","NVOX","LU1988902786.USD","LU0353189763.USD","LU1868837300.USD","LU1868837136.USD","LU1804176565.USD","LU0256863902.USD","BK4599","SG9999013999.USD","LU1917777945.USD","LU0323591593.USD","LU2417539215.USD","IE0004445239.USD","IE00B2B36J28.USD","LU0058720904.USD","LU1064131342.USD","LU0316494557.USD","LU2468319806.SGD","LU0417517546.SGD","LU2552382215.SGD","LU2023250330.USD","LU2236285917.USD","LU2361044865.SGD","LU2111349929.HKD","LU2237438978.USD","LU1023059063.AUD","LU2462157665.USD","LU2491050154.USD","LU2063271972.USD","LU0466842654.USD","SG9999017495.SGD","LU2168563687.JPY","LU0133085943.USD","LU2552382132.HKD","LU1548497426.USD","LU0787776722.HKD","LU1629891620.HKD","LU1267930730.SGD","IE00BFSS7M15.SGD","IE00B7KXQ091.USD","LU2756315318.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641149941","title":"需求扩容抵消降价压力 GLP-1赛道远期市场空间再度上调","url":"https://stock-news.laohu8.com/highlight/detail?id=2641149941","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641149941?lang=zh_cn&edition=full","pubTime":"2026-06-05 23:18","pubTimestamp":1780672735,"startTime":"0","endTime":"0","summary":"金吾财讯 | TD Cowen上调GLP-1药物赛道远期市场预期，预计2030年全球GLP-1药物销售额将达1500亿美元，较此前1390亿美元的预测上调8%，较早年1010亿美元预期大幅抬升。需求端增量是赛道核心支撑，该机构预计2030年全球受益患者规模将从4600万增至5900万，用药需求扩容可对冲行业降价带来的营收压力。今年落地的口服GLP-1制剂商业化潜力突出，预计2030年有望占据全球总销售额的14%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301232","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","LU2023250504.SGD","LU2028103732.USD","LU0106261372.USD","LU2361044949.HKD","LU2461242641.AUD","IE0009355771.USD","SGXZ31699556.SGD","LU0210536198.USD","LU0964807845.USD","LU2756315664.SGD","LU1868837136.USD","LU0823434583.USD","LU0889565916.HKD","IE0004445015.USD","LU2213496289.HKD","IE00B1XK9C88.USD","LU0158827781.USD","LU2602419157.SGD","LU0820562030.AUD","ELIS","LU0133085943.USD","LU2168564222.USD","LU2746668974.SGD","LU1093756325.SGD","SG9999015952.SGD","IE00BFTCPJ56.SGD","LU0320765059.SGD","LU2063271972.USD","LU1323610961.USD","LU0061475181.USD","LU1035775433.USD","LU1280957306.USD","IE00BJJMRY28.SGD","IE00BN29S564.USD","LU0820561818.USD","IE00BK4W5L77.USD","LU0109394709.USD","LU0820561909.HKD","LU1267930730.SGD","IE00BJLML261.HKD","LU1868836591.USD","IE00BK4W5M84.HKD","LU2023251221.USD","LU0154236417.USD","LU0079474960.USD","SGXZ99366536.SGD","LU0238689110.USD","LU0689472784.USD","BK4516","LU2746668461.USD","LU0456855351.SGD","LU2471134796.USD","LU0096364046.USD","LU0417517546.SGD","LU0823434740.USD","LLY","LU0471298777.SGD","LU1548497426.USD","LU2106854487.HKD","LU1145028129.USD","LU2237443382.USD","LU2357305700.SGD","LU2456880835.USD","LU2552382215.SGD","LU1623119135.USD","BK4588","LU2111349929.HKD","LU2168564149.EUR","SG9999001176.SGD","SG9999015978.USD","LU0006306889.USD","LU0471298694.HKD","IE00B775H168.HKD","LU2271345857.HKD","SG9999013999.USD","LU0203201768.USD","SG9999015986.USD","IE00B4JS1V06.HKD","LU2360106947.USD","LU2089984988.USD","LU2168564495.EUR","LU2237443549.SGD","LU0708995401.HKD","LU1983299246.USD","LU2108987350.USD","LU0097036916.USD","LU1064131342.USD","LU1551013342.USD","LU1868836757.USD","LU0353189680.USD","LU2264538146.SGD","LU0354030511.USD","LU0787776722.HKD","LU2361044865.SGD","LU0943347566.SGD","LU0058720904.USD","LU2491049909.HKD","BK4534","LU0432979614.USD","LU1023059063.AUD","LU2237443465.HKD","LU2237443978.SGD","LU1868836914.USD","SG9999014898.SGD","LU0234572021.USD","LU1069344957.HKD","LU2750360997.AUD","IE0005OL40V9.USD","LU0198837287.USD","LU1868837300.USD","IE00BJT1NW94.SGD","LU0094547139.USD","IE00BFSS7M15.SGD","LU1291159041.SGD","SG9999001176.USD","SG9999014880.SGD","LU2491050154.USD","SG9999014914.USD","LU2168564065.EUR","LLYZ","LU1057294990.SGD","BK4007","SG9999017495.SGD","LU0158827948.USD","LU2462157665.USD","LU0109391861.USD","LU2089283258.USD","NVOX","LU1917777945.USD","IE00B1BXHZ80.USD","SG9999018857.SGD","LU1127390331.HKD","LLII","LU2237443895.HKD","SGXZ81514606.USD","LU0353189763.USD","IE00BKPKM429.USD","LU0466842654.USD","LU2361045086.USD","LU2087625088.SGD","SG9999015945.SGD","SG9999018865.SGD","LU2236285917.USD","LU2265009873.SGD","LU1093756168.USD","LU2324357040.USD","IE00BJJMRZ35.SGD","IE00BFSS8Q28.SGD","IE0004445239.USD","LU0225283273.USD","LU1629891620.HKD","LU1988902786.USD","LU2023250330.USD","IE00BKVL7J92.USD","LU2237443622.USD","LU1720051108.HKD","LU2552382132.HKD","LU2756315318.SGD","LU0882574139.USD","LU1720051017.SGD","LU1366192091.USD","LLYX","LU0385154629.USD","LU2237438978.USD","IE00BZ1G4Q59.USD","LU2750360641.GBP","SGXZ51526630.SGD","IE00B7KXQ091.USD","GB00BDT5M118.USD","LU0323591593.USD","NVOH","NVO","LU0683600562.USD","IE00B2B36J28.USD","LU1804176565.USD","LU2468319806.SGD","LU2417539215.USD","IE0001KFT4U8.USD","LU2471134879.HKD","LU2112291526.USD","IE00BKDWB100.SGD","BK4585","LU1232071149.USD","LU2211815571.USD","LU0122379950.USD","LU1974910355.USD","LU2552382058.USD","SGXZ57979304.SGD","IE0002141913.USD","BK4533","LU0882574055.USD","LU1061106388.HKD","LU1551013425.SGD","LU1989771016.USD","LU2896262040.SGD","LU2491050071.SGD","LU0316494557.USD","LU0320765992.SGD","LU2089284900.SGD","IE00BWXC8680.SGD","IE00B4R5TH58.HKD","LU0640476718.USD","LU0256863902.USD","LU0114720955.EUR","ELIL","LU0256863811.USD","LU0786609619.USD","LU1712237335.SGD","LU1814569148.SGD","LU0266013472.USD","BK4532","SG9999014906.USD","LU0289739699.SGD","LU0672654240.SGD","BK4581","IE00BJJMRX11.SGD","LU0203202063.USD","LU0354030438.USD","LU2471134952.CNY","LU2168563687.JPY","LU0823416689.USD","LU2471134523.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185465612","title":"礼来、诺和诺德涨超5%，多项并购、研发进展及产能优化利好共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1185465612","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185465612?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:57","pubTimestamp":1780585052,"startTime":"0","endTime":"0","summary":"近期利好频传。","market":"us","thumbnail":"https://static.tigerbbs.com/383539e68cf14d4cde7a90d97b6a4424","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/383539e68cf14d4cde7a90d97b6a4424"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"986bfebb17fba902db75e9cba66f1f6a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","NVOX","NVO","LLY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1169829532","title":"异动解读｜诺和诺德盘中上涨3.12%，制药板块集体走强叠加口服Wegovy海外拓展提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1169829532","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169829532?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:16","pubTimestamp":1780582564,"startTime":"0","endTime":"0","summary":"6月4日，诺和诺德盘中上涨3.12%，报43.94美元/股，成交额1.44亿美元。消息面上，制药板块集体走强，礼来涨4.05%、默沙东涨4.04%、施贵宝涨3.25%、辉瑞涨1.95%，诺和诺德跟随板块反弹，此前连续两个交易日回调后迎来修复。此外，近期多重利好持续发酵：诺和诺德与合作伙伴Metabolic宣布阿联酋将成为美国以外首个获得口服版Wegovy的市场，临床试验显示口服版64周内平均减重17%；印度亦已批准Wegovy用于12岁及以上青少年群体，适应症拓展持续推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640970210","title":"诺和诺德在阿联酋上市维格维口服减肥药，系美国以外首个落地市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2640970210","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640970210?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:28","pubTimestamp":1780478880,"startTime":"0","endTime":"0","summary":"诺和诺德于阿联酋推出减肥口服药维格维。这是该款药片在美国本土之外的首个上市市场。　　这家丹麦药企周三宣布，减肥口服药维格维正式登陆阿联酋，这也是该药品首次在美国以外地区上市。　　诺和诺德在 5 月初发布一季报时曾透露，在取得各国药监审批后，将于 2026 年下半年在部分海外国家上市这款口服减肥药，当时未披露具体落地国家。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-03/doc-iniacnuq4163888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NVOX","BK4007","IE00BZ1G4Q59.USD","BK4532","BK4588","NVO","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD","NVOH","LU1093756325.SGD","BK4585","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154647672","title":"异动解读｜诺和诺德盘中下跌3.17%，制药板块持续走弱叠加减肥药竞争格局恶化","url":"https://stock-news.laohu8.com/highlight/detail?id=1154647672","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154647672?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:19","pubTimestamp":1780409990,"startTime":"0","endTime":"0","summary":"6月2日，诺和诺德盘中下跌3.17%，报43.425美元/股，成交额3.01亿美元。消息面上，制药板块整体承压，礼来跌1.31%、辉瑞跌0.9%、Zoetis跌1.47%，诺和诺德跟随板块延续弱势。此外，减肥药赛道竞争格局持续恶化：礼来三重激动剂瑞他鲁肽三期数据显示最高减重28.3%，大幅领先诺和诺德CagriSema的22.7%；巴西已批准Ozempic仿制药上市，售价低30%，定价压力加剧。市场对诺和诺德管线竞争力的担忧延续，股价连续两个交易日承压回调。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188955592","title":"异动解读｜诺和诺德盘中下跌3.09%，制药板块整体承压叠加减肥药竞争格局恶化","url":"https://stock-news.laohu8.com/highlight/detail?id=1188955592","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188955592?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:45","pubTimestamp":1780325132,"startTime":"0","endTime":"0","summary":"6月1日，诺和诺德盘中下跌3.09%，报44.18美元/股，成交额1.73亿美元。消息面上，制药板块整体走弱，行业内默沙东跌3.1%、施贵宝跌3.66%、礼来跌2.53%，诺和诺德跟随板块回调。此外，近期多重竞争压力持续发酵：礼来三重激动剂瑞他鲁肽三期数据显示最高减重28.3%，大幅领先诺和诺德CagriSema的22.7%；巴西已批准Ozempic仿制药上市，售价低30%，加剧定价压力。减肥药赛道竞争格局持续向礼来倾斜，市场对诺和诺德管线竞争力的担忧延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640339909","title":"Gate 股票衍生品专区将首发上线 NVO（诺和诺德）、NOK（诺基亚）等 6 个永续合约交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2640339909","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640339909?lang=zh_cn&edition=full","pubTime":"2026-06-01 13:39","pubTimestamp":1780292398,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据官方消息，Gate 股票衍生品专区将于 6 月 1 日 14:00（UTC+8）首发上线 NVO（诺和诺德）、NOK（诺基亚）、ASTS（AST 太空移动）、AAOI（应用光电）、INFQ (Infleqtion)、CRWD（众击）永续合约交易（USDT 结算），支持 1-20 倍杠杆。\n ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2268446","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","NOK","BK4599","BK4585","LU0154236417.USD","NVOX","NVO","BK4007","LU1093756325.SGD","NVOH","BK4020","IE00BKVL7J92.USD","IE00BMPRXN33.USD","GATE","BK4532","BK4588","LNOK","IE00BMPRXR70.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639626600","title":"诺和诺德：印度批准维格维用于青少年群体","url":"https://stock-news.laohu8.com/highlight/detail?id=2639626600","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639626600?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:56","pubTimestamp":1780048560,"startTime":"0","endTime":"0","summary":"诺和诺德印度公司向彭博社书面回应称，印度中央药品标准管控局已批准爆款减肥药Wegovy 上市，适用人群为12周岁及以上、体重超60公斤（132磅） 的青少年。\n　　该企业表示，儿童肥胖问题日益严峻，已成为一大公共健康难题，且会带来长期健康隐患；该药物的使用须由医护人员评估判定。\n　　药企同时指出，这款药物针对青少年的用药剂量与售价将和成人版本保持一致。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：刘明亮","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-29/doc-inhzqimp7582428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","IE00BKVL7J92.USD","LU1093756168.USD","LU1093756325.SGD","NVOH","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4585","BK4599","NVO","NVOX","BK4532","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164391230","title":"异动解读｜诺和诺德盘中上涨3.18%，EASL大会MASH数据发布叠加收购传闻提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1164391230","media":"行情直击","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164391230?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:43","pubTimestamp":1779979415,"startTime":"0","endTime":"0","summary":"5月28日，诺和诺德盘中上涨3.18%，报45.965美元/股，成交额2.53亿美元。消息面上，多重利好共振推动股价走强。首先，诺和诺德正参加EASL 2026肝病年会，集中发布司美格鲁肽2.4mg治疗MASH的关键三期ESSENCE试验核心数据，其中37%患者肝纤维化改善的疗效数据受市场关注。其次，市场传出诺和诺德拟收购丹麦上市公司Zealand Pharma，以补齐胰淀素及双受体靶点布局，增强对礼来的竞争优势。同日制药板块GLP-1赛道整体走强，礼来亦上涨5.56%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":0.0214},{"period":"1month","weight":-0.068},{"period":"3month","weight":0.156},{"period":"6month","weight":-0.1255},{"period":"1year","weight":-0.4586},{"period":"ytd","weight":-0.1376}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.120105},{"month":2,"riseRate":0.6,"avgChangeRate":0.019219},{"month":3,"riseRate":0.444444,"avgChangeRate":0.006415},{"month":4,"riseRate":0.622222,"avgChangeRate":0.018023},{"month":5,"riseRate":0.565217,"avgChangeRate":0.019713},{"month":6,"riseRate":0.673913,"avgChangeRate":0.024791},{"month":7,"riseRate":0.488889,"avgChangeRate":-0.001692},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.048757}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}